Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non-Viral CAR-NK Cell Engineering

Abstract

The recent advancements in cancer immunotherapy have spotlighted the potential of natural killer (NK) cells, particularly chimeric antigen receptor (CAR)–transduced NK cells. These cells, pivotal in innate immunity, offer a rapid and potent response against cancer cells and pathogens without the need for prior sensitization or recognition of peptide antigens. Although NK cell genetic modification is evolving, the viral transduction method continues to be inefficient and fraught with risks, often resulting in cytotoxic outcomes and the possibility of insertional mutagenesis. Consequently, there has been a surge in the development of non-viral transfection technologies to overcome these challenges in NK cell engineering. Non-viral approaches for CAR-NK cell generation are becoming increasingly essential. Cutting-edge techniques such as trogocytosis, electroporation, lipid nanoparticle (LNP) delivery, clustered regularly interspaced short palindromic repeats–associated protein 9 (CRISPR-Cas9) gene editing and transposons not only enhance the efficiency and safety of CAR-NK cell engineering but also open new avenues for novel therapeutic possibilities. Additionally, the infusion of technologies already successful in CAR T-cell therapy into the CAR-NK paradigm holds immense potential for further advancements. In this review, we present an overview of the potential of NK cells in cancer immunotherapies, as well as non-viral transfection technologies for engineering NK cells.

Keywords

chimeric antigen receptor / immunotherapy / natural killer cell / non-viral transfection / tumour microenvironment

References

[1] A. Yilmaz, H. Cui, M. A. Caligiuri, and J. Yu, “Chimeric Antigen Receptor-Engineered Natural Killer Cells for Cancer Immunotherapy,” Journal of Hematology & Oncology 13, no. 1 (2020): 168.

[2] M. B. Khawar and H. Sun, “CAR-NK Cells: From Natural Basis to Design for Kill,” Frontiers in Immunology 12 (2021): 707542.

[3] E. Liu, D. Marin, P. Banerjee, et al., “Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors,” New England Journal of Medicine 382, no. 6 (2020): 545-553.

[4] D. Marin, Y. Li, R. Basar, et al., “Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19(+) B Cell Tumors: A Phase 1/2 Trial,” Nature Medicine 30, no. 3 (2024): 772-784.

[5] G. Ureña-Bailén, J. M. Dobrowolski, Y. Hou, et al., “Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for off-The-Shelf Treatment of AML and B-ALL,” International Journal of Molecular Sciences 23, no. 21 (2022): 12828.

[6] L. Zhang, Y. Meng, X. Feng, and Z. Han, “CAR-NK Cells for Cancer Immunotherapy: From Bench to Bedside,” Biomarker Research 10, no. 1 (2022): 12.

[7] Z. Liu, Z. Zhou, Q. Dang, et al., “Immunosuppression in Tumor Immune Microenvironment and Its Optimization From CAR-T Cell Therapy,” Theranostics 12, no. 14 (2022): 6273-6290.

[8] Z. Zhou, J. Wang, J. Wang, et al., “Deciphering the Tumor Immune Microenvironment From a Multidimensional Omics Perspective: Insight Into Next-Generation CAR-T Cell Immunotherapy and Beyond,” Molecular Cancer 23, no. 1 (2024): 131.

[9] T. R. Abreu, N. A. Fonseca, N. Gonçalves, and J. N. Moreira, “Current Challenges and Emerging Opportunities of CAR-T Cell Therapies,” Journal of Controlled Release 319 (2020): 246-261.

[10] L. Raes, S. C. de Smedt, K. Raemdonck, and K. Braeckmans, “Non-viral Transfection Technologies for Next-Generation Therapeutic T Cell Engineering,” Biotechnology Advances 49 (2021): 107760.

[11] Administration, “FaD. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies,”https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous.

[12] Z. Zhou, G. Zhang, Y. Xu, et al., “The Underlying Mechanism of Chimeric Antigen Receptor (CAR)-T Cell Therapy Triggering Secondary T-Cell Cancers: Mystery of the Sphinx?,” Cancer Letters 597 (2024): 217083.

[13] C. Willyard, “Do Cutting-Edge CAR-T-Cell Therapies Cause Cancer? What the Data Say,” Nature 629, no. 8010 (2024): 22-24.

[14] R. C. Sterner and R. M. Sterner, “CAR-T Cell Therapy: Current Limitations and Potential Strategies,” Blood Cancer Journal 11, no. 4 (2021): 69.

[15] A. Shimabukuro-Vornhagen, P. Gödel, M. Subklewe, et al., “Cytokine Release Syndrome,” Journal for Immunotherapy of Cancer 6, no. 1 (2018): 56.

[16] S. M. Albelda, “CAR T Cell Therapy for Patients With Solid Tumours: Key Lessons to Learn and Unlearn,” Nature Reviews. Clinical Oncology 21, no. 1 (2024): 47-66.

[17] L. Labanieh and C. L. Mackall, “CAR Immune Cells: Design Principles, Resistance and the Next Generation,” Nature 614, no. 7949 (2023): 635-648.

[18] K. Drougkas, K. Karampinos, I. Karavolias, et al., “Comprehensive Clinical Evaluation of CAR-T Cell Immunotherapy for Solid Tumors: A Path Moving Forward or a Dead End?,” Journal of Cancer Research and Clinical Oncology 149, no. 6 (2023): 2709-2734.

[19] A. D. Miller, “Retrovirus Packaging Cells,” Human Gene Therapy 1, no. 1 (1990): 5-14.

[20] N. Verdun and P. Marks, “Secondary Cancers After Chimeric Antigen Receptor T-Cell Therapy,” New England Journal of Medicine 390 (2024): 584-586.

[21] P. D. Moço, N. Aharony, and A. Kamen, “Adeno-Associated Viral Vectors for Homology-Directed Generation of CAR-T Cells,” Biotechnology Journal 15, no. 1 (2020): e1900286.

[22] J. Zhang, Y. Hu, J. Yang, et al., “Non-viral, Specifically Targeted CAR-T Cells Achieve High Safety and Efficacy in B-NHL,” Nature 609, no. 7926 (2022): 369-374.

[23] Y. Gong, R. G. J. Klein Wolterink, J. Wang, G. M. J. Bos, and W. T. V. Germeraad, “Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Design and Engineering for Cancer Therapy,” Journal of Hematology & Oncology 14, no. 1 (2021): 73.

[24] E. S. Allen, D. F. Stroncek, J. Ren, et al., “Autologous Lymphapheresis for the Production of Chimeric Antigen Receptor T Cells,” Transfusion 57, no. 5 (2017): 1133-1141.

[25] J. H. Park, I. Rivière, M. Gonen, et al., “Long-Term Follow-Up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia,” New England Journal of Medicine 378, no. 5 (2018): 449-459.

[26] Y. Hu, J. Sun, Z. Wu, et al., “Predominant Cerebral Cytokine Release Syndrome in CD19-Directed Chimeric Antigen Receptor-Modified T Cell Therapy,” Journal of Hematology & Oncology 9, no. 1 (2016): 70.

[27] M. Shao, Q. Yu, X. Teng, et al., “CRS-Related Coagulopathy in BCMA Targeted CAR-T Therapy: A Retrospective Analysis in a Phase I/II Clinical Trial,” Bone Marrow Transplantation 56, no. 7 (2021): 1642-1650.

[28] J. N. Brudno and J. N. Kochenderfer, “Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management,” Blood Reviews 34 (2019): 45-55.

[29] K. Pan, H. Farrukh, V. Chittepu, H. Xu, C. X. Pan, and Z. Zhu, “CAR Race to Cancer Immunotherapy: From CAR T, CAR NK to CAR Macrophage Therapy,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 119.

[30] Y. Zhang, D. L. Wallace, C. M. de Lara, et al., “In Vivo Kinetics of Human Natural Killer Cells: The Effects of Ageing and Acute and Chronic Viral Infection,” Immunology 121, no. 2 (2007): 258-265.

[31] G. K. Antony and A. Z. Dudek, “Interleukin 2 in Cancer Therapy,” Current Medicinal Chemistry 17, no. 29 (2010): 3297-3302.

[32] I. Pedroza-Pacheco, A. Madrigal, and A. Saudemont, “Interaction Between Natural Killer Cells and Regulatory T Cells: Perspectives for Immunotherapy,” Cellular & Molecular Immunology 10, no. 3 (2013): 222-229.

[33] A. Rodriguez-Garcia, A. Palazon, E. Noguera-Ortega, D. J. Powell, and S. Guedan, “CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape,” Frontiers in Immunology 11 (2020): 1109.

[34] C. K. Looi, F. F. Chung, C. O. Leong, S. F. Wong, R. Rosli, and C. W. Mai, “Therapeutic Challenges and Current Immunomodulatory Strategies in Targeting the Immunosuppressive Pancreatic Tumor Microenvironment,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 162.

[35] J. Hilpert, L. Grosse-Hovest, F. Grünebach, et al., “Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses,” Journal of Immunology 189, no. 3 (2012): 1360-1371.

[36] K. S. Reiners, D. Topolar, A. Henke, et al., “Soluble Ligands for NK Cell Receptors Promote Evasion of Chronic Lymphocytic Leukemia Cells From NK Cell Anti-Tumor Activity,” Blood 121, no. 18 (2013): 3658-3665.

[37] A. Valeri, A. García-Ortiz, E. Castellano, et al., “Overcoming Tumor Resistance Mechanisms in CAR-NK Cell Therapy,” Frontiers in Immunology 13 (2022): 953849.

[38] E. Marcenaro, C. Cantoni, S. Pesce, et al., “Uptake of CCR7 and Acquisition of Migratory Properties by Human KIR+ NK Cells Interacting With Monocyte-Derived DC or EBV Cell Lines: Regulation by KIR/HLA-Class I Interaction,” Blood 114, no. 19 (2009): 4108-4116.

[39] S. S. Somanchi, A. Somanchi, L. J. Cooper, and D. A. Lee, “Engineering Lymph Node Homing of Ex Vivo-Expanded Human Natural Killer Cells via Trogocytosis of the Chemokine Receptor CCR7,” Blood 119, no. 22 (2012): 5164-5172.

[40] F. N. Cho, T. H. Chang, C. W. Shu, et al., “Enhanced Cytotoxicity of Natural Killer Cells Following the Acquisition of Chimeric Antigen Receptors Through Trogocytosis,” PLoS One 9, no. 10 (2014): e109352.

[41] J. H. Liu, S. Wei, D. K. Blanchard, and J. Y. Djeu, “Restoration of Lytic Function in a Human Natural Killer Cell Line by Gene Transfection,” Cellular Immunology 156, no. 1 (1994): 24-35.

[42] L. Boissel, M. Betancur, W. S. Wels, H. Tuncer, and H. Klingemann, “Transfection With mRNA for CD19 Specific Chimeric Antigen Receptor Restores NK Cell Mediated Killing of CLL Cells,” Leukemia Research 33, no. 9 (2009): 1255-1259.

[43] N. Shimasaki, H. Fujisaki, D. Cho, et al., “A Clinically Adaptable Method to Enhance the Cytotoxicity of Natural Killer Cells Against B-Cell Malignancies,” Cytotherapy 14, no. 7 (2012): 830-840.

[44] L. Li, C. Allen, R. Shivakumar, and M. V. Peshwa, “Large Volume Flow Electroporation of mRNA: Clinical Scale Process,” Methods in Molecular Biology 969 (2013): 127-138.

[45] T. Ingegnere, F. R. Mariotti, A. Pelosi, et al., “Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing,” Frontiers in Immunology 10 (2019): 957.

[46] L. Xiao, D. Cen, H. Gan, et al., “Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients,” Molecular Therapy 27, no. 6 (2019): 1114-1125.

[47] Y. Y. Ng, Z. Du, X. Zhang, W. J. Chng, and S. Wang, “CXCR4 and Anti-BCMA CAR Co-Modified Natural Killer Cells Suppress Multiple Myeloma Progression in a Xenograft Mouse Model,” Cancer Gene Therapy 29, no. 5 (2022): 475-483.

[48] G. Roex, D. Campillo-Davo, D. Flumens, et al., “Two for One: Targeting BCMA and CD19 in B-Cell Malignancies With Off-The-Shelf Dual-CAR NK-92 Cells,” Journal of Translational Medicine 20, no. 1 (2022): 124.

[49] E. L. Siegler, Y. J. Kim, X. Chen, et al., “Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers,” Molecular Therapy 25, no. 12 (2017): 2607-2619.

[50] T. Nakamura, T. Nakade, Y. Sato, and H. Harashima, “Delivering mRNA to a Human NK Cell Line, NK-92 Cells, by Lipid Nanoparticles,” International Journal of Pharmaceutics 636 (2023): 122810.

[51] V. Golubovskaya, J. Sienkiewicz, J. Sun, et al., “CAR-NK Cells Generated With mRNA-LNPs Kill Tumor Target Cells in Vitro and in Vivo,” International Journal of Molecular Sciences 24, no. 17 (2023): 13364.

[52] S. Douka, L. E. Brandenburg, C. Casadidio, et al., “Lipid Nanoparticle-Mediated Messenger RNA Delivery for Ex Vivo Engineering of Natural Killer Cells,” Journal of Controlled Release 361 (2023): 455-469.

[53] T. Brown, “Observations by Immunofluorescence Microscopy and Electron Microscopy on the Cytopathogenicity of Naegleria fowleri in Mouse Embryo-Cell Cultures,” Journal of Medical Microbiology 12, no. 3 (1979): 363-371.

[54] E. Joly and D. Hudrisier, “What Is Trogocytosis and What Is Its Purpose?,” Nature Immunology 4, no. 9 (2003): 815.

[55] T. Lu, R. Ma, Z. Li, et al., “Hijacking TYRO3 From Tumor Cells via Trogocytosis Enhances NK-Cell Effector Functions and Proliferation,” Cancer Immunology Research 9, no. 10 (2021): 1229-1241.

[56] M. S. Hasim, M. Marotel, J. J. Hodgins, et al., “When Killers Become Thieves: Trogocytosed PD-1 Inhibits NK Cells in Cancer,” Science Advances 8, no. 15 (2022): eabj3286.

[57] S. J. Judge, W. J. Murphy, and R. J. Canter, “Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence,” Frontiers in Cellular and Infection Microbiology 10 (2020): 49.

[58] M. Poorebrahim, J. Melief, Y. Pico de Coaña, S. L. Wickström, A. Cid-Arregui, and R. Kiessling, “Counteracting CAR T Cell Dysfunction,” Oncogene 40, no. 2 (2021): 421-435.

[59] C. R. Good, M. A. Aznar, S. Kuramitsu, et al., “An NK-Like CAR T Cell Transition in CAR T Cell Dysfunction,” Cell 184, no. 25 (2021): 6081-6100.e6026.

[60] Y. Li, R. Basar, G. Wang, et al., “KIR-Based Inhibitory CARs Overcome CAR-NK Cell Trogocytosis-Mediated Fratricide and Tumor Escape,” Nature Medicine 28, no. 10 (2022): 2133-2144.

[61] M. Hamieh, A. Dobrin, A. Cabriolu, et al., “CAR T Cell Trogocytosis and Cooperative Killing Regulate Tumour Antigen Escape,” Nature 568, no. 7750 (2019): 112-116.

[62] F. Ramezani, A. R. Panahi Meymandi, B. Akbari, et al., “Outsmarting Trogocytosis to Boost CAR NK/T Cell Therapy,” Molecular Cancer 22, no. 1 (2023): 183.

[63] M. Carlsten and R. W. Childs, “Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications,” Frontiers in Immunology 6 (2015): 266.

[64] M. Carlsten, E. Levy, A. Karambelkar, et al., “Efficient mRNA-Based Genetic Engineering of Human NK Cells With High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC Against Lymphoma and Targets NK Cell Migration Toward the Lymph Node-Associated Chemokine CCL19,” Frontiers in Immunology 7 (2016): 105.

[65] A. J. Wilk, N. L. Weidenbacher, R. Vergara, et al., “Charge-Altering Releasable Transporters Enable Phenotypic Manipulation of Natural Killer Cells for Cancer Immunotherapy,” Blood Advances 4, no. 17 (2020): 4244-4255.

[66] H. Akita, K. Kogure, R. Moriguchi, et al., “Reprint of: Nanoparticles for Ex Vivo siRNA Delivery to Dendritic Cells for Cancer Vaccines: Programmed Endosomal Escape and Dissociation,” Journal of Controlled Release 149, no. 1 (2011): 58-64.

[67] L. O. Afolabi, A. O. Adeshakin, M. M. Sani, J. Bi, and X. Wan, “Genetic Reprogramming for NK Cell Cancer Immunotherapy With CRISPR/Cas9,” Immunology 158, no. 2 (2019): 63-69.

[68] M. Gurney, A. Stikvoort, E. Nolan, et al., “CD38 Knockout Natural Killer Cells Expressing an Affinity Optimized CD38 Chimeric Antigen Receptor Successfully Target Acute Myeloid Leukemia With Reduced Effector Cell Fratricide,” Haematologica 107, no. 2 (2022): 437-445.

[69] F. Jiang and J. A. Doudna, “CRISPR-Cas9 Structures and Mechanisms,” Annual Review of Biophysics 46 (2017): 505-529.

[70] D. Stenger, T. A. Stief, T. Kaeuferle, et al., “Endogenous TCR Promotes In Vivo Persistence of CD19-CAR-T Cells Compared to a CRISPR/Cas9-Mediated TCR Knockout CAR,” Blood 136, no. 12 (2020): 1407-1418.

[71] A. Biederstädt and K. Rezvani, “Engineering the Next Generation of CAR-NK Immunotherapies,” International Journal of Hematology 114, no. 5 (2021): 554-571.

[72] L. O. Afolabi, M. O. Afolabi, M. M. Sani, et al., “Exploiting the CRISPR-Cas9 Gene-Editing System for Human Cancers and Immunotherapy,” Clin Transl Immunology 10, no. 6 (2021): e1286.

[73] K. Sekiba, M. Yamagami, M. Otsuka, et al., “Transcriptional Activation of the MICA Gene With an Engineered CRISPR-Cas9 System,” Biochemical and Biophysical Research Communications 486, no. 2 (2017): 521-525.

[74] T. Bexte, J. Alzubi, L. M. Reindl, et al., “CRISPR-Cas9 Based Gene Editing of the Immune Checkpoint NKG2A Enhances NK Cell Mediated Cytotoxicity Against Multiple Myeloma,” Oncoimmunology 11, no. 1 (2022): 2081415.

[75] E. J. Pomeroy, J. T. Hunzeker, M. G. Kluesner, et al., “A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy,” Molecular Therapy 28, no. 1 (2020): 52-63.

[76] M. Daher, R. Basar, E. Gokdemir, et al., “Targeting a Cytokine Checkpoint Enhances the Fitness of Armored Cord Blood CAR-NK Cells,” Blood 137, no. 5 (2021): 624-636.

[77] B. L. Solomon and I. Garrido-Laguna, “TIGIT: A Novel Immunotherapy Target Moving From Bench to Bedside,” Cancer Immunology, Immunotherapy 67, no. 11 (2018): 1659-1667.

[78] R. S. Huang, H. A. Shih, M. C. Lai, Y. J. Chang, and S. Lin, “Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins,” Frontiers in Immunology 11 (2020): 1008.

[79] E. Haapaniemi, S. Botla, J. Persson, B. Schmierer, and J. Taipale, “CRISPR-Cas9 Genome Editing Induces a p53-Mediated DNA Damage Response,” Nature Medicine 24, no. 7 (2018): 927-930.

[80] C. T. Charlesworth, P. S. Deshpande, D. P. Dever, et al., “Identification of Preexisting Adaptive Immunity to Cas9 Proteins in Humans,” Nature Medicine 25, no. 2 (2019): 249-254.

[81] C. B. Mc, “The Origin and Behavior of Mutable Loci in Maize,” Proceedings of the National Academy of Sciences of the United States of America 36, no. 6 (1950): 344-355.

[82] N. Sandoval-Villegas, W. Nurieva, M. Amberger, and Z. Ivics, “Contemporary Transposon Tools: A Review and Guide Through Mechanisms and Applications of Sleeping Beauty, piggyBac and Tol2 for Genome Engineering,” International Journal of Molecular Sciences 22, no. 10 (2021): 5084.

[83] Z. Ivics, P. B. Hackett, R. H. Plasterk, and Z. Izsvák, “Molecular Reconstruction of Sleeping Beauty, a Tc1-Like Transposon From Fish, and Its Transposition in Human Cells,” Cell 91, no. 4 (1997): 501-510.

[84] L. Ye, S. Z. Lam, L. Yang, et al., “AAV-Mediated Delivery of a Sleeping Beauty Transposon and an mRNA-Encoded Transposase for the Engineering of Therapeutic Immune Cells,” Nature Biomedical Engineering 8, no. 2 (2024): 132-148.

[85] L. Chicaybam, L. Abdo, M. Viegas, et al., “Transposon-Mediated Generation of CAR-T Cells Shows Efficient Anti B-Cell Leukemia Response After Ex Vivo Expansion,” Gene Therapy 27, no. 1-2 (2020): 85-95.

[86] R. Hodge, S. A. Narayanavari, Z. Izsvák, and Z. Ivics, “Wide Awake and Ready to Move: 20 Years of Non-Viral Therapeutic Genome Engineering With the Sleeping Beauty Transposon System,” Human Gene Therapy 28, no. 10 (2017): 842-855.

[87] M. Amberger and Z. Ivics, “Latest Advances for the Sleeping Beauty Transposon System: 23 Years of Insomnia but Prettier Than Ever: Refinement and Recent Innovations of the Sleeping Beauty Transposon System Enabling Novel, Nonviral Genetic Engineering Applications,” BioEssays 42, no. 11 (2020): e2000136.

[88] L. Mátés, M. K. Chuah, E. Belay, et al., “Molecular Evolution of a Novel Hyperactive Sleeping Beauty Transposase Enables Robust Stable Gene Transfer in Vertebrates,” Nature Genetics 41, no. 6 (2009): 753-761.

[89] S. Ding, X. Wu, G. Li, M. Han, Y. Zhuang, and T. Xu, “Efficient Transposition of the piggyBac (PB) Transposon in Mammalian Cells and Mice,” Cell 122, no. 3 (2005): 473-483.

[90] J. Cadiñanos and A. Bradley, “Generation of an Inducible and Optimized piggyBac Transposon System,” Nucleic Acids Research 35, no. 12 (2007): e87.

[91] K. Yusa, L. Zhou, M. A. Li, A. Bradley, and N. L. Craig, “A Hyperactive piggyBac Transposase for Mammalian Applications,” Proceedings of the National Academy of Sciences of the United States of America 108, no. 4 (2011): 1531-1536.

[92] L. E. Woodard, X. Li, N. Malani, et al., “Comparative Analysis of the Recently Discovered hAT Transposon TcBuster in Human Cells,” PLoS One 7, no. 11 (2012): e42666.

[93] A. Koga, M. Suzuki, H. Inagaki, Y. Bessho, and H. Hori, “Transposable Element in Fish,” Nature 383, no. 6595 (1996): 30.

[94] X. Li, H. Ewis, R. H. Hice, et al., “A Resurrected Mammalian hAT Transposable Element and a Closely Related Insect Element Are Highly Active in Human Cell Culture,” Proceedings of the National Academy of Sciences of the United States of America 110, no. 6 (2013): E478-E487.

[95] M. Gurney, E. O'Reilly, S. Corcoran, et al., “Concurrent Transposon Engineering and CRISPR/Cas9 Genome Editing of Primary CLL-1 Chimeric Antigen Receptor-Natural Killer Cells,” Cytotherapy 24, no. 11 (2022): 1087-1094.

[96] A. W. Nienhuis, C. E. Dunbar, and B. P. Sorrentino, “Genotoxicity of Retroviral Integration in Hematopoietic Cells,” Molecular Therapy 13, no. 6 (2006): 1031-1049.

[97] C. J. Braun, K. Boztug, A. Paruzynski, et al., “Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity,” Science Translational Medicine 6, no. 227 (2014): 227ra233.

[98] D. C. Bishop, L. E. Clancy, R. Simms, et al., “Development of CAR T-Cell Lymphoma in 2 of 10 Patients Effectively Treated With piggyBac-Modified CD19 CAR T Cells,” Blood 138, no. 16 (2021): 1504-1509.

[99] A. Gogol-Döring, I. Ammar, S. Gupta, et al., “Genome-Wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4(+) T Cells,” Molecular Therapy 24, no. 3 (2016): 592-606.

[100] S. Prommersberger, M. Reiser, J. Beckmann, et al., “CARAMBA: A First-In-Human Clinical Trial With SLAMF7 CAR-T Cells Prepared by Virus-Free Sleeping Beauty Gene Transfer to Treat Multiple Myeloma,” Gene Therapy 28, no. 9 (2021): 560-571.

[101] C. F. Magnani, G. Gaipa, D. Belotti, et al., “Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered With Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL),” Blood 134, no. Supplement_1 (2019): 200.

[102] S. Arai, R. Meagher, M. Swearingen, et al., “Infusion of the Allogeneic Cell Line NK-92 in Patients With Advanced Renal Cell Cancer or Melanoma: A Phase I Trial,” Cytotherapy 10, no. 6 (2008): 625-632.

[103] M. Boyiadzis, M. Agha, R. L. Redner, et al., “Phase 1 Clinical Trial of Adoptive Immunotherapy Using ‘Off-The-Shelf’ Activated Natural Killer Cells in Patients With Refractory and Relapsed Acute Myeloid Leukemia,” Cytotherapy 19, no. 10 (2017): 1225-1232.

[104] Y. Galat, S. Dambaeva, I. Elcheva, et al., “Cytokine-Free Directed Differentiation of Human Pluripotent Stem Cells Efficiently Produces Hemogenic Endothelium With Lymphoid Potential,” Stem Cell Research & Therapy 8, no. 1 (2017): 67.

[105] D. A. Knorr, Z. Ni, D. Hermanson, et al., “Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy,” Stem Cells Translational Medicine 2, no. 4 (2013): 274-283.

[106] C. Dege, K. H. Fegan, J. P. Creamer, et al., “Potently Cytotoxic Natural Killer Cells Initially Emerge From Erythro-Myeloid Progenitors During Mammalian Development,” Developmental Cell 53, no. 2 (2020): 229-239.e227.

[107] Y. Li, D. L. Hermanson, B. S. Moriarity, and D. S. Kaufman, “Human iPSC-Derived Natural Killer Cells Engineered With Chimeric Antigen Receptors Enhance Anti-Tumor Activity,” Cell Stem Cell 23, no. 2 (2018): 181-192.e185.

[108] P. S. Knoepfler, “Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells,” Regenerative Medicine 7, no. 5 (2012): 713-720.

[109] D. A. Lee, “Cellular Therapy: Adoptive Immunotherapy With Expanded Natural Killer Cells,” Immunological Reviews 290, no. 1 (2019): 85-99.

[110] R. Li, R. Johnson, G. Yu, D. H. McKenna, and A. Hubel, “Preservation of Cell-Based Immunotherapies for Clinical Trials,” Cytotherapy 21, no. 9 (2019): 943-957.

[111] M. Awan, I. Buriak, R. Fleck, et al., “Dimethyl Sulfoxide: A Central Player Since the Dawn of Cryobiology, Is Efficacy Balanced by Toxicity?,” Regenerative Medicine 15, no. 3 (2020): 1463-1491.

[112] X. Yao and S. Matosevic, “Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy,” BioDrugs 35, no. 5 (2021): 529-545.

[113] B. Min, H. Choi, J. H. Her, et al., “Optimization of Large-Scale Expansion and Cryopreservation of Human Natural Killer Cells for Anti-Tumor Therapy,” Immune Network 18, no. 4 (2018): e31.

[114] X. Yao, J. J. Jovevski, M. F. Todd, et al., “Nanoparticle-Mediated Intracellular Protection of Natural Killer Cells Avoids Cryoinjury and Retains Potent Antitumor Functions,” Advanced Science (Weinh) 7, no. 9 (2020): 1902938.

[115] R. Xu, X. Shi, H. Huang, W. S. Tan, and H. Cai, “Development of a me(2)SO-Free Cryopreservation Medium and Its Long-Term Cryoprotection on the CAR-NK Cells,” Cryobiology 114 (2023): 104835.

[116] J. Rich, Z. Tian, and T. J. Huang, “Sonoporation: Past, Present, and Future,” Advanced Materials Technologies 7, no. 1 (2022): 2100885.

[117] A. Delalande, S. Kotopoulis, M. Postema, P. Midoux, and C. Pichon, “Sonoporation: Mechanistic Insights and Ongoing Challenges for Gene Transfer,” Gene 525, no. 2 (2013): 191-199.

[118] J. Deprez, G. Lajoinie, Y. Engelen, S. C. de Smedt, and I. Lentacker, “Opening Doors With Ultrasound and Microbubbles: Beating Biological Barriers to Promote Drug Delivery,” Advanced Drug Delivery Reviews 172 (2021): 9-36.

[119] Y. J. Ho, J. P. Li, C. H. Fan, H. L. Liu, and C. K. Yeh, “Ultrasound in Tumor Immunotherapy: Current Status and Future Developments,” Journal of Controlled Release 323 (2020): 12-23.

[120] I. Lentacker, I. de Cock, R. Deckers, S. C. de Smedt, and C. T. Moonen, “Understanding Ultrasound Induced Sonoporation: Definitions and Underlying Mechanisms,” Advanced Drug Delivery Reviews 72 (2014): 49-64.

[121] W. Xu, X. Zhang, X. Hu, C. Zhiyi, and P. Huang, “Translational Prospects of Ultrasound-Mediated Tumor Immunotherapy: Preclinical Advances and Safety Considerations,” Cancer Letters 460 (2019): 86-95.

[122] J. N. Belling, L. K. Heidenreich, Z. Tian, et al., “Acoustofluidic Sonoporation for Gene Delivery to Human Hematopoietic Stem and Progenitor Cells,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 20 (2020): 10976-10982.

[123] A. Karki, E. Giddings, A. Carreras, et al., “Sonoporation as an Approach for siRNA Delivery Into T Cells,” Ultrasound in Medicine & Biology 45, no. 12 (2019): 3222-3231.

[124] M. L. de Temmerman, H. Dewitte, R. E. Vandenbroucke, et al., “mRNA-Lipoplex Loaded Microbubble Contrast Agents for Ultrasound-Assisted Transfection of Dendritic Cells,” Biomaterials 32, no. 34 (2011): 9128-9135.

[125] S. Y. Wu, C. H. Wang, S. T. Kang, C. F. Yu, F. H. Chen, and C. S. Chiang, “Power-Doppler-Based NH002 Microbubble Sonoporation With Chemotherapy Relieves Hypoxia and Enhances the Efficacy of Chemotherapy and Immunotherapy for Pancreatic Tumors,” Scientific Reports 14, no. 1 (2024): 8532.

[126] X. Duan, S. Y. Lo, J. C. Y. Lee, J. M. F. Wan, and A. C. H. Yu, “Sonoporation of Immune Cells: Heterogeneous Impact on Lymphocytes, Monocytes and Granulocytes,” Ultrasound in Medicine & Biology 48, no. 7 (2022): 1268-1281.

[127] R. Xiong, F. Sauvage, J. C. Fraire, C. Huang, S. C. de Smedt, and K. Braeckmans, “Photothermal Nanomaterial-Mediated Photoporation,” Accounts of Chemical Research 56, no. 6 (2023): 631-643.

[128] L. Raes, S. Stremersch, J. C. Fraire, et al., “Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation,” Nano-Micro Letters 12, no. 1 (2020): 185.

[129] A. Harizaj, M. Wels, L. Raes, et al., “Photoporation With Biodegradable Polydopamine Nanosensitizers Enables Safe and Efficient Delivery of mRNA in Human T Cells,” Advanced Functional Materials 31 (2021): 2102472.

[130] D. Berdecka, A. Harizaj, I. Goemaere, et al., “Delivery of Macromolecules in Unstimulated T Cells by Photoporation With Polydopamine Nanoparticles,” Journal of Controlled Release 354 (2023): 680-693.

[131] R. Xiong, D. Hua, J. van Hoeck, et al., “Photothermal Nanofibres Enable Safe Engineering of Therapeutic Cells,” Nature Nanotechnology 16, no. 11 (2021): 1281-1291.

[132] M. P. Stewart, R. Langer, and K. F. Jensen, “Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts,” Chemical Reviews 118, no. 16 (2018): 7409-7531.

[133] A. Harizaj, S. C. de Smedt, I. Lentacker, and K. Braeckmans, “Physical Transfection Technologies for Macrophages and Dendritic Cells in Immunotherapy,” Expert Opinion on Drug Delivery 18, no. 2 (2021): 229-247.

[134] A. K. Shalek, J. T. Gaublomme, L. Wang, et al., “Nanowire-Mediated Delivery Enables Functional Interrogation of Primary Immune Cells: Application to the Analysis of Chronic Lymphocytic Leukemia,” Nano Letters 12, no. 12 (2012): 6498-6504.

[135] V. Bhingardive, G. Le Saux, A. Edri, A. Porgador, and M. Schvartzman, “Nanowire Based Guidance of the Morphology and Cytotoxic Activity of Natural Killer Cells,” Small 17, no. 14 (2021): e2007347.

[136] Y. Chen, A. R. Shokouhi, N. H. Voelcker, and R. Elnathan, “Nanoinjection: A Platform for Innovation in Ex Vivo Cell Engineering,” Accounts of Chemical Research 57, no. 12 (2024): 1722-1735.

[137] C. Focaccetti, M. Benvenuto, C. Pighi, et al., “DNAM-1-Chimeric Receptor-Engineered NK Cells, Combined With Nutlin-3a, More Effectively Fight Neuroblastoma Cells In Vitro: A Proof-Of-Concept Study,” Frontiers in Immunology 13 (2022): 886319.

[138] P. S. Adusumilli, L. Cherkassky, J. Villena-Vargas, et al., “Regional Delivery of Mesothelin-Targeted CAR T Cell Therapy Generates Potent and Long-Lasting CD4-Dependent Tumor Immunity,” Science Translational Medicine 6, no. 261 (2014): 261ra151.

[139] R. Alkins, A. Burgess, R. Kerbel, W. S. Wels, and K. Hynynen, “Early Treatment of HER2-Amplified Brain Tumors With Targeted NK-92 Cells and Focused Ultrasound Improves Survival,” Neuro-Oncology 18, no. 7 (2016): 974-981.

[140] C. S. Centner, J. T. Moore, M. E. Baxter, K. Yaddanapudi, P. J. Bates, and J. A. Kopechek, “Comparison of Acoustofluidic and Static Systems for Ultrasound-Mediated Molecular Delivery to T Lymphocytes,” Ultrasound in Medicine & Biology 49, no. 1 (2023): 90-105.

[141] A. R. Shokouhi, Y. Chen, H. Z. Yoh, et al., “Engineering Efficient CAR-T Cells via Electroactive Nanoinjection,” Advanced Materials 35, no. 44 (2023): e2304122.

[142] D. Kim, S. Jo, D. Lee, et al., “NK Cells Encapsulated in Micro/Macropore-Forming Hydrogels via 3D Bioprinting for Tumor Immunotherapy,” Biomaterials Research 27, no. 1 (2023): 60.

[143] H. Li, Y. Yang, W. Hong, M. Huang, M. Wu, and X. Zhao, “Applications of Genome Editing Technology in the Targeted Therapy of Human Diseases: Mechanisms, Advances and Prospects,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 1.

[144] Z. Wang, G. Wang, H. Lu, H. Li, M. Tang, and A. Tong, “Development of Therapeutic Antibodies for the Treatment of Diseases,” Molecular Biomedicine 3, no. 1 (2022): 35.

[145] K. G. Daniels, S. Wang, M. S. Simic, et al., “Decoding CAR T Cell Phenotype Using Combinatorial Signaling Motif Libraries and Machine Learning,” Science 378, no. 6625 (2022): 1194-1200.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.